{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T07:50:16Z","timestamp":1784015416743,"version":"3.55.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/ http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Critical limb-threatening ischaemia is a life-threatening disease which often combines with infrapopliteal arterial disease. Percutaneous transluminal angioplasty (PTA) is recommended as the first-line treatment for infrapopliteal arterial disease. Drug-eluting stent (DES) is another widely used option; however, its long-term therapeutic effect is controversial. The effectiveness of different DES for infrapopliteal arterial disease needs further exploration.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods and results:<\/jats:title>\n            <jats:p>The PubMed, EMBASE, Cochrane Library and Clinical trials were systematically searched from inception to 1 February 2023. Literatures were included if the study was original, peer-reviewed, published in English or Chinese, and contained patients diagnosed with simple infrapopliteal arterial disease or with properly treated combined inflow tract lesions before or during the study procedure. A total of 953 patients, 504 in the DES group and 449 in the PTA\/bare-metal stenting (BMS) group, from 12 randomised controlled trials were included in the meta-analysis. The results showed that DES is superior to control group for improving clinical patency, reducing the restenosis rate, and reducing the amputation rate at 6 months, 1 year, and 3 years post-treatment [at 3 years, risk ratio (RR): 1.90, 95% CI 1.23\u20132.93; RR: 0.87, 95% CI 0.79\u20130.96; RR: 0.60, 95% CI 0.36\u20131.00, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.049]. In addition, subgroup analyses suggested that DES is superior to BMS and PTA in improving clinical patency and reducing target lesion revascularisation and restenosis rates at 6-month and 1-year post-treatment. The network meta-analysis indicated that sirolimus-eluting stent was superior for improving clinical patency (at 1 year, RR: 0.23, 95% CI 0.08\u20130.60) and reducing the restenosis rate (at 6 months, RR: 31.58, 95% CI 4.41\u2013307.53, at 1 year, RR: 3.80, 95% CI 1.84\u20138.87) significantly. However, according to the cumulative rank probabilities test, everolimus-eluting stent may have the lowest target lesion revascularisation rates and amputation rates at 1-year post-treatment (the cumulative rank probability was 77% and 49%, respectively).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This systematic review and network meta-analysis showed that DES was associated with more clinical efficacy than PTA\/BMS significantly. In addition, sirolimus-eluting stent and everolimus-eluting stent may have better clinical benefits.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/js9.0000000000000736","type":"journal-article","created":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T05:14:07Z","timestamp":1695014047000},"page":"4286-4297","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Comparation of drug-eluting stents and control therapy for the treatment of infrapopliteal artery disease: a Bayesian analysis"],"prefix":"10.1097","volume":"109","author":[{"given":"Yang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XuWei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,12]]},"reference":[{"key":"R1-20250824","doi-asserted-by":"crossref","first-page":"e002938","DOI":"10.1161\/JAHA.115.002938","article-title":"Critical limb ischemia: current trends and future directions","volume":"5","author":"Teraa","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"R2-20250824","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.jacc.2015.12.049","article-title":"Peripheral artery disease: evolving role of exercise, medical therapy, and endovascular options","volume":"67","author":"Olin","year":"2016","journal-title":"J Am College Cardiol"},{"issue":"1s","key":"R3-20250824","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ejvs.2019.05.006","article-title":"Global vascular guidelines on the management of chronic limb-threatening ischemia","volume":"58","author":"Conte","year":"2019","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"R4-20250824","doi-asserted-by":"crossref","first-page":"e003468","DOI":"10.1161\/CIRCINTERVENTIONS.115.003468","article-title":"Percutaneous transluminal angioplasty in patients with infrapopliteal arterial disease: systematic review and meta-analysis","volume":"9","author":"Mustapha","year":"2016","journal-title":"Circ Cardiovasc Intervent"},{"key":"R5-20250824","first-page":"205","article-title":"Drug-coated vs uncoated percutaneous transluminal angioplasty in infrapopliteal arteries: six-month results of the Lutonix BTK Trial.","volume":"31","author":"Mustapha","year":"2019","journal-title":"J Invasive Cardiol"},{"key":"R6-20250824","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.3390\/jcm9103321","article-title":"Infrapopliteal artery occlusive disease: an overview of vessel preparation and treatment options","volume":"9","author":"Tummala","year":"2020","journal-title":"J Clin Med"},{"key":"R7-20250824","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ijsu.2017.06.075","article-title":"Drug-eluting stents versus control therapy in the infrapopliteal disease: A meta-analysis of eight randomized controlled trials and two cohort studies","volume":"44","author":"Liu","year":"2017","journal-title":"Int J Surg (London, England)"},{"key":"R8-20250824","doi-asserted-by":"crossref","first-page":"121","DOI":"10.23736\/S0392-9590.19.04049-5","article-title":"The use of drug-eluting stents in infrapopliteal arteries: an updated systematic review and meta-analysis of randomized trials","volume":"38","author":"Varcoe","year":"2019","journal-title":"Int Angiol"},{"key":"R9-20250824","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/1538574416689426","article-title":"Systematic review and meta-analysis of drug-eluting balloon and stent for infrapopliteal artery revascularization","volume":"51","author":"Zhang","year":"2017","journal-title":"Vasc Endovasc Surg"},{"key":"R10-20250824","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1177\/1526602816671740","article-title":"Comparative effectiveness of plain balloon angioplasty, bare metal stents, drug-coated balloons, and drug-eluting stents for the treatment of infrapopliteal artery disease: systematic review and Bayesian Network Meta-analysis of Randomized Controlled Trials","volume":"23","author":"Katsanos","year":"2016","journal-title":"J Endovasc Ther"},{"key":"R11-20250824","doi-asserted-by":"crossref","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg (London, England)"},{"key":"R13-20250824","first-page":"258","article-title":"Clinical effect of drug-eluting stents implantation and balloon expansion in treatment of patients with knee artery lesions","volume":"31","author":"Tao","year":"2015","journal-title":"Clin Med China"},{"key":"R14-20250824","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jvs.2011.07.099","article-title":"Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease","volume":"55","author":"Bosiers","year":"2012","journal-title":"J Vasc Surg"},{"key":"R15-20250824","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1007\/s00330-008-1225-1","article-title":"The evaluation of primary stenting of sirolimus-eluting versus bare-metal stents in the treatment of atherosclerotic lesions of crural arteries","volume":"19","author":"Falkowski","year":"2009","journal-title":"Eur Radiol"},{"key":"R16-20250824","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s00270-020-02602-6","article-title":"10-year paclitaxel dose-related outcomes of drug-eluting stents treated below the knee in patients with chronic limb-threatening ischemia (The PADI Trial)","volume":"43","author":"Konijn","year":"2020","journal-title":"Cardiovasc Intervent Radiol"},{"key":"R17-20250824","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.jacc.2012.04.035","article-title":"Sirolimus-eluting stents for treatment of infrapopliteal arteries reduce clinical event rate compared to bare-metal stents: long-term results from a randomized trial","volume":"60","author":"Rastan","year":"2012","journal-title":"J Am College Cardiol"},{"key":"R18-20250824","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1093\/eurheartj\/ehr144","article-title":"Sirolimus-eluting stents vs. bare-metal stents for treatment of focal lesions in infrapopliteal arteries: a double-blind, multi-centre, randomized clinical trial","volume":"32","author":"Rastan","year":"2011","journal-title":"Eur Heart J"},{"key":"R19-20250824","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1016\/j.jacc.2012.08.989","article-title":"A prospective randomized multicenter comparison of balloon angioplasty and infrapopliteal stenting with the sirolimus-eluting stent in patients with ischemic peripheral arterial disease: 1-year results from the ACHILLES trial","volume":"60","author":"Scheinert","year":"2012","journal-title":"J Am College Cardiol"},{"key":"R20-20250824","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jvir.2009.05.031","article-title":"Infrapopliteal application of sirolimus-eluting versus bare metal stents for critical limb ischemia: analysis of long-term angiographic and clinical outcome","volume":"20","author":"Siablis","year":"2009","journal-title":"J Vasc Intervent Radiol"},{"key":"R21-20250824","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.jcin.2014.04.015","article-title":"Paclitaxel-coated balloon angioplasty versus drug-eluting stenting for the treatment of infrapopliteal long-segment arterial occlusive disease: the IDEAS randomized controlled trial","volume":"7","author":"Siablis","year":"2014","journal-title":"JACC Cardiovasc Intervent"},{"key":"R22-20250824","doi-asserted-by":"crossref","first-page":"e002376","DOI":"10.1161\/CIRCINTERVENTIONS.114.002376","article-title":"Percutaneous transluminal angioplasty and drug-eluting stents for infrapopliteal lesions in critical limb ischemia (PADI) trial","volume":"9","author":"Spreen","year":"2016","journal-title":"Circ Cardiovasc Intervent"},{"key":"R23-20250824","doi-asserted-by":"crossref","first-page":"e004877","DOI":"10.1161\/JAHA.116.004877","article-title":"Long-term follow-up of the PADI trial: percutaneous transluminal angioplasty versus drug-eluting stents for infrapopliteal lesions in critical limb ischemia","volume":"6","author":"Spreen","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"R24-20250824","first-page":"203","article-title":"Drug eluting stents versus PTA with GP IIb\/IIIa blockade below the knee in patients with current ulcers\u2014The BELOW Study","volume":"51","author":"Tepe","year":"2010","journal-title":"J Cardiovasc Surg"},{"key":"R25-20250824","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jcin.2016.03.006","article-title":"Drug-coated balloons for long superficial femoral artery disease: leaving nothing behind in the real-world","volume":"9","author":"Armstrong","year":"2016","journal-title":"JACC Cardiovasc Intervent"},{"key":"R26-20250824","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13019-021-01452-8","article-title":"A meta-analysis of everolimus-eluting stents versus sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients","volume":"16","author":"Ouyang","year":"2021","journal-title":"J Cardiothorac Surg"},{"key":"R27-20250824","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.1038\/s41598-017-06705-y","article-title":"Long-term (2-5 years) adverse clinical outcomes associated with ZES versus SES, PES and EES: a meta-analysis","volume":"7","author":"Bundhun","year":"2017","journal-title":"Sci Rep"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000000736","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T19:16:55Z","timestamp":1756063015000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000000736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,14]]},"references-count":26,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000000736","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,14]]},"assertion":[{"value":"2023-05-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}